medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2013, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (4)

Treatment of autoimmune hemolytic anemias

Alfonso VME, Bencomo HA

Language: Spanish
References: 48
Page:
PDF size: 236.73 Kb.


ABSTRACT

The treatment of autoimmune hemolytic anemias (AIHA) is based on the individual clinical evaluation, immunochemical characteristics of the involved antibodies and the absence or presence of an underlying condition. The treatment of AIHAs varies according to its immunohematological classification. The steroids are the first line therapy for AIHA due to warm antibodies (wAIHA). After the initial remission, the doses should be reduced slowly, until the required maintenance level is reached; steroid-dependent or steroid resistant patients often require splenectomy or treatment with Rituximab (anti CD20 monoclonal antibody) and with less frequency, immunosuppressive drugs as azathioprine or cyclophosphamide. Patients with cold AIHA agglutinins (cAHAI) are resistant to steroids and splenectomy; patients with asymptomatic or stable anemia do not require treatment. Rituximab is the most effective treatment for symptomatic cases, although immunosuppressants such as cyclophosphamide and chlorambucil could be used. Paroxysmal cold hemoglobinuria do not usually require treatment. Mixed type AIHAs may be treated similarly to those with wAIHA. Drug induced AIHAs usually respond to discontinuing the offending drug and steroids treatment. Transfusion should be avoided in AIHAs, except in life threatening situations; if it is required, small volumes of erytrhocyte concentrates should be administered, slowly, in cAIHA; the blood should be prewarmed at 370 C.


REFERENCES

  1. Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr. 2008;120(5-6):136-51.

  2. Petz LD. Diagnostic complexities in autoimmune hemolytic anemias. Transfusion. 2009 Feb;49(2):202-3.

  3. Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev. 2008 Jan;22(1):1-15.

  4. Bencomo A, Alfonso ME, Alfonso Y, Salazar MY. Procedimientos para la determinación e identificación de anticuerpos eritrocitarios. Pruebas de compatibilidad pretransfusional. En: Suardíaz J, Cruz C, Colina A: Laboratorio Clínico. La Habana:Ciencias Médicas; 2004. p. 575-92.

  5. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010 Sep 16;116(11):1831-8.

  6. Guía de práctica clínica. Diagnóstico y tratamiento de la anemia hemolítica autoinmune. México: secretaria de Salud; 2010. (citado 3 de dic 2012). Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/389_GPC_Diagnostico_y_tratamiento_de_ANEMIA_HEMOLITICA_AUTOINMUNE/GER_ANEMIA_HOMOLITICA_AUTOINMUNE_ADQUIRIDA.pdf

  7. López M. Anemias hemolíticas autoinmunes, 2010. (citado 26 dic 2012). Disponible en: http://www.mgyf.org/medicinageneral/revista_127/pdf/186-191.pdf

  8. Alfonso ME, Bencomo AA, Cortina L, Hernández P, López MR. Medicina Transfusional. En: Suardíaz J, Cruz C, Colina A. Laboratorio Clínico. La Habana:Ciencias Médicas; 2004.p. 611-45

  9. Naithani R, Agrawal N, Mahapatra M, Kumar R, Pati HP, Choudhry VP. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol. 2007 Jun;24(4):309-15.

  10. Gupta V, Shukla J, Bhatia BD. Autoimmune hemolytic anemia.Indian J Pediatr. 2008 May;75(5):451-4.

  11. Alfonso ME, Bencomo AA, Espinosa E, Guerrero R, Guerra E, Guerrero AI. Caracterización de pacientes adultos con anemia hemolítica autoinmune atendidos en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter. [serie en internet]. 2009 Dic [citado 3 dic 2012]; 25(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892009000300005&lng=es

  12. Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011 Dec;4(6):607-18.

  13. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults Blood. 2011 Oct; 118(15): 4036-40.

  14. Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol. 2001 Nov;8(6):411-6.

  15. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002 Jul 15;100:704-6

  16. Navarro A, Jimenez I, Galera AM, Fuster JL. Micofenolato mofetilo como alternativa de tratamiento de la anemia hemolítica autoinmunitaria crónica corticodependiente An Pediatr (Barc). 2012 Jul;77(1):64-5.

  17. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005 Jul;75(1):60-4.

  18. Farruggia P, Macaluso A, Tropia S, Genova S, Paolicchi O, Di Marco F, et al. Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory evans syndrome. Pediatr Rep. 2011 Jun 16;3(2):e15.

  19. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther. 2007 Jul-Aug;20(4):229-38.

  20. Brauer DL, Edelman B, Rapoport AP, Hess JR, Akpek G. Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease. Transfusion.2012 Nov;52(11):2432-5.

  21. Mangan KF, Besa EC, Shadduck RK, Tedrow H, Ray PK. Demonstration of two distinct antibodies in autoimmune hemolytic anemia with reticulocytopenia and red cell aplasia. Exp Hematol. 1984;12(10):788–93.

  22. Arbach O, Funck R, Seibt F, Salama A. Erythropoietin May Improve Anemia in Patients with Autoimmune Hemolytic Anemia Associated with Reticulocytopenia. Transfus Med Hemother. 2012 Jun;39(3):221-3.

  23. Kuzmanovic M, Jurisic V. Rituximab for treatment of autoimmune hemolytic anemia. Indian Pediatr. 2012 Aug;49(8):672-4.

  24. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant. 2001 Nov;28(9):903-5.

  25. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for Refractory Evans Syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004 Nov;77(3):303-10.

  26. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001 Nov 3;358(9292):1511-3.

  27. Fozza C, Longinoti M. Use of Rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas Adv Hematol. 2011; 2011: 960137.

  28. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003 Nov;78(11):1340-6.

  29. D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Filippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006 Aug;81(8):598-602.

  30. Berentsen S. How I manage cold agglutinin disease. Br J Haematol. 2011 May;153(3):309-17.

  31. Mease, PJ. B-cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008 Jul;35(7):1245-55.

  32. D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):62-8.

  33. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009 Nov;266(5):484-91.

  34. Song KW, Mollee P, Patterson B, Brien W, Crump M. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002 Oct;119(1):125-7.

  35. Bermudez A,Marco F, Conde E, Mazo E, RecioM, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica. 2000 Aug;85(8):894-5.

  36. Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002 Sep;100(6):2257-9.

  37. Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following Rituximab therapy in children. Haematologica. 2006 Aug;91(8 Suppl):ECR36.

  38. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia Curr Hematol Malig Rep. 2009 Jan;4(1):47-53.

  39. Reda G, Maura F, Gritti G, Gregorini A, Binda F, Guidotti F, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol. 2012 Sep;87(9):936-7.

  40. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8.

  41. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant. 2001 Nov;28(9):903-5.

  42. Dacie, J. Treatment and prognosis of cold antibody AIHA. En: Dacie J ed. The Haemolytic Anaemias. London:Churchill Livingstone; 1992 .p. 502–8.

  43. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004 Apr 15;103(8):2925-8.

  44. Tanaka H, Hashimoto S, Sugita Y, Sakai S, Takeda Y, Abe D, et al. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy. Int J Hematol. 2012 Oct;96(4):501-5.

  45. Roth A, Hüttmann A, Rother RP, Dührsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood. 2009 Apr 16;113(16):3885-6.

  46. Siami FS, Siami GA. A last resort modality using cryofiltration apheresis for the treatment of cold hemagglutinin disease in a Veterans Administration hospital. Ther Apher Dial. 2004 Oct;8(5):398-403.

  47. Win N, Tiwari D, Keevil VL, Needs M, Lakhani A. Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T-cell angioimmunoblastic non-Hodgkin's lymphoma. Pediatr Hematol Oncol. 2007 Apr;12(2):159-62.

  48. Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012 Jul;11(4):635-42.




2020     |     www.medigraphic.com